NASD · Healthcare · Biotechnology · USA
Arrowhead Pharmaceuticals Inc is a mid cap company (market value between $2 billion and $10 billion) in the Biotechnology industry.
Arrowhead Pharmaceuticals creates therapeutic treatments for difficult-to-treat diseases by using RNA interference to suppress genes responsible for disease. The company maintains drug candidates in various clinical trial phases and recently launched REDEMPLO, its first approved medicine, which lowers triglycerides in patients with Familial Chylomicronemia Syndrome. Through partnerships with biotech and pharmaceutical firms, Arrowhead licenses out certain programs while retaining commercial rights to its own pipeline.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Arrowhead Pharmaceuticals Inc stock.
Overvalued: intrinsic value $12.07 per share, market price $57.23, margin of safety -374.2% (as of 2026-10-19).
Discounting its cash flows at 11.1% (average of 2 methods) values the shares at $12.07; the price of $57.23 is 374% above that value, and 71% of that value comes from beyond year five.
Leak Score: 34/100 on 8 of 12 signals (On Watch).
17 more funds hold it; the full list is part of the paid plan.
88 more in this industry show a wider margin of safety.
ARWR is overvalued (as of the 2026-10-19 close). Discounting its cash flows at 11.1% (average of 2 methods) values the shares at $12.07; the price of $57.23 is 374% above that value, and 71% of that value comes from beyond year five.
$12.07 per share (as of the 2026-10-19 close), against a market price of $57.23. That is a margin of safety of -374.2%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
34 out of 100, which we rate "On Watch", on 8 of 12 value investing signals.